1. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial;Bresalier;N Engl J Med,2005
2. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis;Jüni;Lancet,2004
3. Failing the public health – rofecoxib, Merck, and the FDA;Topol;N Engl J Med,2004
4. Associated Press. Merck scores in Alabama court over Vioxx drug. Wall Street J 2006;(December 16):A5.
5. Merck’s Vioxx Information Center. [Accessed March 12, 2007].